Allergan trims fat to halt takeover

Share this article:

Allergan is trimming the fat as part of efforts to head off a possible takeover by Valeant, two sources confirmed to Bloomberg. The company's restructuring plan is thought to include company-wide cost cuts, including some “legacy expenses,” the news service reported.

Allergan has rebuffed Valeant's last three offers since April, saying the offers do not reflect Allergan's value. Allergan CEO David Pyott set a five-year plan for cost-cutting targets in motion after the company rejected Valeant's initial bid.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.